-
Product Insights
NewNet Present Value Model: SELLAS Life Sciences Group Inc’s Galinpepimut-S
Empower your strategies with our Net Present Value Model: SELLAS Life Sciences Group Inc's Galinpepimut-S report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Consumer Insights
NewMass Affluent Banking in Western Europe – Regional Breakdown by Market Trends, Investment Preferences and Competitor Benchmarking
Mass Affluent Banking Market in Western Europe Report Overview Western Europe has an attractively large segment of the mass affluent population accounting for over 90% of the liquid asset value invested in the region. Equities and mutual funds are the most popular assets besides private pensions and investment properties. Achieving a financially secure and comfortable retirement is the main financial goal of mass affluents. Hence, a large percentage of them prefer accumulating assets instead of repaying their debts. This indicates...
-
Product Insights
NewNet Present Value Model: SELLAS Life Sciences Group Inc’s NeuVax
Empower your strategies with our Net Present Value Model: SELLAS Life Sciences Group Inc's NeuVax report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
Italy Cards and Payments – Opportunities and Risks to 2027
GlobalData’s ‘Italy Cards and Payments: Opportunities and Risks to 2027' report provides detailed analysis of market trends in the Italian cards and payments industry. It provides values and volumes for a number of key performance indicators in the industry, including cash, cards, credit transfers, direct debits and cheques during the review-period (2019–23e). The report also analyzes various payment card markets operating in the industry and provides detailed information on the number of cards in circulation, transaction values and volumes during...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLS-009 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLS-009 in Lymphoma Drug Details: SLS-009 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLS-009 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLS-009 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLS-009 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLS-009 in Diffuse Large B-Cell Lymphoma Drug Details: SLS-009...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLS-009 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLS-009 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: SLS-009...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLS-009 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLS-009 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLS-009 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLS-009 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...